RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (United States)

Structure/Sequence

Sequence Code 453117726

Source: *****

Sequence Code 453117729

Source: *****

Clinical Trials associated with Efanesoctocog alfa

NCT06941870

/ Not yet recruitingPhase 4

Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.
The study duration for each participant is approximately 12 months.

Start Date30 May 2025

Sponsor / Collaborator

Sanofi

NCT06940830

/ RecruitingPhase 4

A Low-interventional Study to Evaluate Long-term Effectiveness of Real-world Prophylactic Treatment With Efanesoctocog Alfa on Joint Health in People With Haemophilia A (ALTITUDE)

The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.

Start Date21 May 2025

Sponsor / Collaborator

Swedish Orphan Biovitrum AB

[+1]

NCT06716814

/ RecruitingPhase 3

A Multinational, Prospective, Open-label, Roll-over Study (LIBERTY) to Provide Post-trial Access to Treatment for Patients With Severe Haemophilia A Who Have Completed a Previous Trial With Efanesoctocog Alfa

This is a multinational, prospective, open-label, roll-over study in patients with severe haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study (LTS16294), FREEDOM study (Sobi.BIVV001-001), or PK comparison study (Sobi.BIVV001-003). The aim of the study is to provide patients with continuous benefit from efanesoctocog alfa treatment and to further continue clinical monitoring for safety and efficacy until efanesoctocog alfa is commercially available in each patient's respective country (or until March 2027, whichever comes first).
The study starts with the Baseline Visit, which will be done in connection to the End of Study visit (or equivalent) in the respective parent study. Subsequent study visits (on site or phone call) will be done approximately every 13 weeks until End of Treatment. An End of Study safety phone call will be done 14 (+7) days after the End of Treatment Visit.

Start Date06 Mar 2025

Sponsor / Collaborator

Swedish Orphan Biovitrum AB

[+1]

100 Clinical Results associated with Efanesoctocog alfa

100 Translational Medicine associated with Efanesoctocog alfa

100 Patents (Medical) associated with Efanesoctocog alfa

Literatures (Medical) associated with Efanesoctocog alfa

01 Jul 2025·JOURNAL OF CLINICAL PHARMACOLOGY

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

Article

Author: Katragadda, Suresh ; Macha, Sreeraj ; Nyberg, Joakim ; Bhagunde, Pratik ; Benson, Craig ; Wong, Nancy ; Willemze, Annemieke ; Demissie, Marek

Abstract:

Efanesoctocog alfa is a first‐in‐class high‐sustained factor VIII (HSF) replacement therapy for treatment of hemophilia A. This article presents population pharmacokinetics (PopPK) of efanesoctocog alfa and repeated time‐to‐event (RTTE) analysis of bleeding episodes in adults/adolescents (≥12 years of age) and children (<12 years). The final PopPK dataset contained pooled data from 277 patients (4405 post‐dose factor VIII [FVIII] activity records) from two Phase 1/2a studies (NCT03205163; EudraCT 2018‐001535‐51), and three Phase 3 studies, XTEND‐1 (NCT04161495), XTEND‐Kids (NCT04759131), and XTEND‐ed (NCT04644575). The PopPK model developed was a linear one‐compartment model including body weight effect on clearance and volume of central compartment; Asian race was identified as a statistically significant covariate on clearance. The final PopPK model adequately described the FVIII activity–time profiles in adults, adolescents, and children with once‐weekly (QW) efanesoctocog alfa 50 IU/kg, consistent with experience in XTEND‐1 and XTEND‐Kids. Bleeding episodes in participants in XTEND‐1 and XTEND‐Kids were characterized by an RTTE model with a Weibull base hazard and effect of FVIII activity modeled by a power effect. The RTTE model showed the probability of being bleed‐free in 1 year with efanesoctocog alfa 50 IU/kg QW regimen was >70% across all age groups, consistent with the observed clinical outcomes in the Phase 3 trials of highly effective protection from bleeding episodes in patients with severe hemophilia A, which validates the model's prediction of the long‐term bleed hazard.

01 Jul 2025·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe haemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial

Article

Author: Malec, Lynn ; Bystrická, Linda ; Santagostino, Elena ; Gunawardena, Sriya ; Wong, Nancy ; Dunn, Amy L ; Khan, Umer ; Nolan, Beatrice ; Neill, Graham ; Peyvandi, Flora ; Tarango, Cristina ; Mathias, Mary

BACKGROUND:

Once-weekly efanesoctocog alfa (50 IU/kg) provided high-sustained factor VIII (FVIII) activity and robust bleed protection in previously treated children with severe haemophilia A.

OBJECTIVE:

This post hoc analysis presents additional bleed treatment and pharmacokinetic (PK) outcomes from the XTEND-Kids study (NCT04759131).

PATIENTS/METHODS:

XTEND-Kids was a Phase 3, open-label study in previously treated children <12 years with severe haemophilia A. Participants received once-weekly efanesoctocog alfa (50 IU/kg) prophylaxis for 52 weeks. Annualised bleed rate (ABR), bleed treatment, response to treatment, PK, and safety outcomes, including immunogenicity, were assessed.

RESULTS:

Once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) provided high-sustained FVIII levels in the normal to near-normal range (>40 IU/dL) for 3 days and >10 IU/dL for ∼7 days at steady state; PK parameters were similar in participants with blood groups O and non-O. Efanesoctocog alfa prophylaxis resulted in effective bleed protection with zero bleeds in 64% of participants and consistently low ABRs. The rate of spontaneous and traumatic bleeding episodes per week remained consistently low throughout the 52-week study period. A single dose of efanesoctocog alfa resolved 95% of bleeding episodes, regardless of type or location. The haemostatic efficacy of efanesoctocog alfa for the treatment of bleeding episodes was rated as excellent or good for nearly all evaluated first injections (97%). No inhibitors or unexpected safety findings were reported.

CONCLUSION:

Once-weekly prophylaxis with efanesoctocog alfa provided high-sustained FVIII levels and highly effective bleed treatment and prevention in previously treated children <12 years of age with severe haemophilia A.

01 Jul 2025·JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease

Article

Author: Zilberstein, Moshe ; Yarramaneni, Abhimanyu ; Susen, Sophie ; Wong, Nancy ; Seth Chhabra, Ekta ; Mamikonian, Lara ; Santagostino, Elena ; Trossaërt, Marc ; Willemze, Annemieke

BACKGROUND:

Efanesoctocog alfa is a high-sustained factor (F)VIII replacement therapy for hemophilia A. The D'D3 domain of efanesoctocog alfa overcomes the von Willebrand factor-imposed half-life ceiling and may allow correction of reduced FVIII levels experienced by people with type 2N or type 3 von Willebrand disease (VWD).

OBJECTIVES:

This study aimed to assess the pharmacokinetics, safety, and tolerability of efanesoctocog alfa in type 2N or type 3 VWD.

METHODS:

This was a phase 1, open-label study of efanesoctocog alfa in adults with hereditary type 2N or type 3 VWD (NCT04770935). Participants received a single intravenous dose of efanesoctocog alfa (25 IU/kg). The primary end point was pharmacokinetic parameters as determined by noncompartmental analysis of efanesoctocog alfa FVIII activity using one-stage assay and capture chromogenic assay, the latter of which is more relevant in assessing FVIII levels from efanesoctocog alfa among people with VWD. Secondary end points included adverse events and FVIII inhibitor development.

RESULTS:

Six participants were assessed (type 2N, n = 2; type 3, n = 4). One dose of efanesoctocog alfa of 25 IU/kg maintained FVIII activity levels of >1 IU/dL up to 10 days postdose. Mean baseline-corrected FVIII activity levels were maintained at >40 and >10 IU/dL up to 1 day and 4 days postdose, respectively, per capture chromogenic assay. Mean (standard deviation) t_1/2z was 49.0 (10.2) hours. Efanesoctocog alfa was well tolerated. FVIII inhibitors or antidrug antibodies were not detected.

CONCLUSION:

Efanesoctocog alfa is well-tolerated and maintains high FVIII activity levels for a prolonged period in patients with type 2N or type 3 VWD.

121

News (Medical) associated with Efanesoctocog alfa

31 Jul 2025

·www.globenewswire.com

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% to €1.2 billion Research and Development expenses were €1.9 billion, up 17.7% Selling, general and administrative expenses were €2.3 billion, up 7.8% Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24 Pipeline progress Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US) Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology Capital allocation Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio’s DR-0201, early-stage pipeline in immunology Acquisitions announced: Vigil, in Alzheimer’s disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3 Sustainability Sanofi ranked the world’s tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME Guidance In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4 Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date Paul Hudson, Chief Executive Officer: “We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth.” Q2 2025 Change Change at CER H1 2025 Change Change at CER IFRS net sales reported €9,994m +6.0% +10.1% €19,889m +8.3% +9.9% IFRS net income reported €3,939m +253.9% — €5,812m +158.8% — IFRS EPS reported €3.24 +264.0% — €4.74 +163.3% — Free cash flow5 €1,429m +65.8% — €2,458m +474.3% — Business operating income €2,461m -2.4% +3.3 % €5,363m +8.6% +10.8% Business net income €1,940m -0.6% +5.1 % €4,152m +7.6% +9.8% Business EPS €1.59 +1.9% +8.3% €3.39 +9.7% +12.0% 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4. 3 Subject to closing conditions detailed overleaf. 4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS. 5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9). Attachment Press release

AcquisitionVaccinePhase 3Drug ApprovalBreakthrough Therapy

31 Jul 2025

·www.biospace.com

Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025

iStock, wildpixel For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU. Sanofi CFO François Roger has expressed confidence that tariffs will have little impact on the company in 2025. Speaking on Sanofi’s second-quarter results earnings call, Roger said it is difficult to predict the impact because of uncertainty about what actions the White House will take. The trade deal with the European Union establishes a 15% tariff on imports from Europe, where Sanofi is based, but CEO Paul Hudson told investors it remains unclear whether “it’s a 15% tariff with a caveat or a 15-plus or a 15-less.” Amid the uncertainty, Sanofi has run various scenarios based on the proposals reported in the media to understand how tariffs could affect finances in 2025. The models suggest Sanofi has little to fear for now. “We did not factor it in our guidance, but it will have a limited impact on 2025 because we already have inventory in place in the U.S.,” Roger said. “With what we know today and what we read in the media, we don’t think that it will impact our guidance in any way for 2025.” Hudson fielded a broader question about tariffs, Most Favored Nation pricing and the balance in funding for innovative drugs between the U.S. and Europe. Hudson said nobody knows what will happen but Sanofi is prepared for delivering guidance this year, “so don’t feel we’re casual about it because we’re absolutely not.” President Donald Trump has accused other countries of freeloading, fueling debate about differences in drug prices and healthcare spending between the U.S. and EU. Hudson made the case for EU countries putting in place the budgets to ensure patients can access innovative therapies. “There’s a lot of people who could contribute to economies and GDP if medicines were made available to them,” Hudson said. “I’m as interested in budgets for health giving access to innovation for more patients as I am in the price conversation. We will see where it nets out. As a healthcare company, we’d like to see more patients get access.” Hudson was speaking after Sanofi reported 10.1% sales growth at a constant exchange rate in the second quarter. The growth led Sanofi to predict a high single-digit percentage increase in sales for the full year. Sanofi’s revised forecast narrows its 2025 outlook at the top end of the previously predicted mid-to-high single-digit range. Dupixent drove growth in the second quarter. Supported by its launch in chronic obstructive pulmonary disease, Dupixent sales grew more than 20% to 3.8 billion euros ($4.3 billion). Sales of three of Sanofi’s other main medicines—Lantus, Toujeo and Praluent—grew by 10% or more. Sanofi attributed the growth in sales of the long-acting insulin Lantus to windfall sales due to the unavailability of competing medicines. Sales of nine newly launched medicines and vaccines rose 47.3%. Hemophilia A therapy Altuviiio led the way with revenues of 291 million euros ($333 million), an increase of more than 90% over the second quarter of 2024. Sanofi said growth of Altuviiio, which the FDA approved in 2023, was driven by patients switching from older plasma-derived and recombinant factor medicines and to a lesser extent from non-factor drugs.

Drug Approval

24 Jul 2025

·www.fiercepharma.com

Sanofi lends support to ‘Dismissed’ film about 5 women’s experiences with hemophilia

This isn’t the first time Sanofi has sponsored a film spotlighting the experiences of people with bleeding disorders. In 2020, the Big Pharma lent its financial support to another Believe Limited production called “Let’s Talk.” A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female patients go misdiagnosed for years and often feel ignored or overlooked by healthcare providers.Sanofi provided financial support for the film, which was produced by patient engagement agency Believe Limited. The French drugmaker sells several treatments for the bleeding disorder, including Qfitlia, Altuviiio, Alprolix and Eloctate.“Dismissed” is slated to premiere on Aug. 22 at the National Bleeding Disorders Foundation’s (NBDF’s) Bleeding Disorders Conference in Colorado.The film follows four women diagnosed with hemophilia—a 15-year-old patient advocate, a mother-to-be looking for a clear treatment plan, a woman left paralyzed by a preventable complication and the chief operating officer of the NBDF—as well as a mother of two sons with the disease who begins to suspect her own longtime symptoms might be due to undiagnosed hemophilia.The documentary catalogues the women’s struggles with misdiagnoses, lack of treatment plans and the feeling of being dismissed by doctors, as well as their efforts to care for family members with the disease and advocate for the broader hemophilia community. Hemophilia is typically associated with men, and many people mistakenly believe that women can only be benign carriers of the disease—a common misconception about X-linked disorders that Sanofi is also working to correct.According to statistics cited by the film’s makers, 80% of hemophilia clinical trials recruit only men. Nearly 60% of healthcare providers have reported diagnostic delays for women with hemophilia, with Black women often experiencing even more significant delays due to systemic and racial biases in the healthcare system. The film’s website offers several resources for viewers who want to further support the hemophilia community, including downloadable social media assets to spread the word about the documentary; a “screening toolkit” of educational information, activity ideas and tips for empowering women in conversations with their doctors; and a link to “be part of the solution” by locating nearby clinical trials.“The women in this film have been dismissed time and time again, and their stories demand attention,” Bella Gadsby, the film’s director, said in a statement. “Working at Believe Limited, I’ve witnessed firsthand the impact of advocacy and the power of storytelling in shifting perspectives. This film is not just about hemophilia; it’s about the systemic silencing of women and the urgent need to change the narrative. ‘Dismissed’ is not just a documentary, it’s a declaration.”This isn’t the first time Sanofi has sponsored a film spotlighting the experiences of people with bleeding disorders: In 2020, the Big Pharma lent its financial support to another Believe Limited production, “Let’s Talk,” which homed in on the mental health aspect of life with hemophilia and other bleeding disorders.Elsewhere, in 2023, the company released the results of a survey it began shortly after Altuviiio’s FDA approval, highlighting hemophilia patients’ unmet needs and hopes for future treatments.

Clinical Study

100 Deals associated with Efanesoctocog alfa

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemophilia A	United States	Bioverativ, Inc.	22 Feb 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhage	Phase 3	United States	Biogen, Inc.	23 Feb 2021
Hemorrhage	Phase 3	United States	Sanofi (China) Investment Co. Ltd.	23 Feb 2021
Hemorrhage	Phase 3	United States	Bioverativ Therapeutics, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Belgium	Bioverativ Therapeutics, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Belgium	Sanofi (China) Investment Co. Ltd.	23 Feb 2021
Hemorrhage	Phase 3	Belgium	Biogen, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Bulgaria	Bioverativ Therapeutics, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Bulgaria	Sanofi (China) Investment Co. Ltd.	23 Feb 2021
Hemorrhage	Phase 3	Bulgaria	Biogen, Inc.	23 Feb 2021
Hemorrhage	Phase 3	Canada	Bioverativ Therapeutics, Inc.	23 Feb 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


XTEND-1 and XTEND-Kids (Pubmed \| Haemophilia)	Phase 3	Hemophilia A factor VIII (FVIII) activity levels	-	Efanesoctocog alfa 50 IU/kg	mrvaalsliz(rgfrcuvaun) = ppjoicufaj smuxyphoxc (fujcgxcyxy, 45 - 361)	Positive	18 Mar 2025
ASH2024	Not Applicable	Hemophilia A	-	Efanesoctocog Alfa	imjitzkoti(qbypqquydj) = One PwHA experienced an infusion reaction after the fourth dose rcytiawfnp (sdqgvoddwe ) View more	-	07 Dec 2024
NCT04161495 (XTEND-1, Pubmed \| Clin Ther)	Phase 3	Hemophilia A	159	Efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks	lxfpamrotu(cwfwoyfcsc) = cbftiesazc sqackwnjed (iawlybyfmo ) View more	Positive	01 Dec 2024
NCT04759131 (XTEND-Kids, PRNewswire) Manual	Phase 3	Hemophilia A	73	ALTUVOCT	phqimghube(xlkxhmtcin) = qzusflggeh drpvjyboze (vmxwafbwre, 0.42–0.90) View more	Positive	18 Jul 2024
NCT04759131 (XTEND-Kids, Pubmed)	Phase 3	Hemophilia A	74	Efanesoctocog alfa	ieiiiyryda(djicmlcmux) = Most adverse events were nonserious. No serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa were reported. vvyfqvvuru (vsibpcdhnx )	Positive	18 Jul 2024
NCT05042440 (Phase 1 sequential pharmacokinetic study, EHA2024) Manual	Phase 1	Hemophilia A FVIII	13	Octocog alfa	lewwslbuer(acocnehmro) = ywwdgivwpm askvrwdiiz (nnitanujqf ) View more	Positive	14 May 2024
	Phase 1	Hemophilia A FVIII	13	Rurioctocog alfa pegol	lewwslbuer(acocnehmro) = uhdxhdgssq askvrwdiiz (nnitanujqf ) View more	Positive	14 May 2024
NCT04759131 (XTEND-Kids, CTgov)	Phase 3	Hemophilia A	74	efanesoctocog alfa (BIVV001) (BIVV001: Participants Aged <6 Years)	mszxhpykug = hkmjyyevrt uxjtgapmtt (ikqadidphv, qmktlhlyph - hasmjfpqlm) View more	-	13 Feb 2024
NCT04759131 (XTEND-Kids, CTgov)	Phase 3	Hemophilia A	74	efanesoctocog alfa (BIVV001) (BIVV001: Participants Aged 6 to <12 Years)	mszxhpykug = iflzaxtduj uxjtgapmtt (ikqadidphv, qpcazwuzlz - lkdedqomww) View more	-	13 Feb 2024
NCT04161495 (XTEND-1, ISTH2023)	Phase 3	Hemophilia A	78	Standard-of-care FVIII prophylaxis	khdqgbnqap(wpjuobfedn) = almqbxoacx metamsyppm (ywbgmwfrzl )	-	24 Jun 2023
NCT04161495 (XTEND-1, ISTH2023)	Phase 3	Hemophilia A	78	Efanesoctocog alfa 50 IU/kg prophylaxis	khdqgbnqap(wpjuobfedn) = ploxjpqcdt metamsyppm (ywbgmwfrzl )	-	24 Jun 2023
NCT04161495 (XTEND-1, ASH 12022 \| ASH 22022) Manual	Phase 3	Hemophilia A	159	Efanesoctocog alfa	sqxobjkvmm(bdxdaofxwk) = xcyzuvabwl oihygrgida (yrjsaiaehf ) View more	Positive	15 Nov 2022
NCT04161495 (XTEND-1, ASH 12022 \| ASH 22022) Manual	Phase 3	Pain \| Hemophilia A	159	Efanesoctocog alfa (Arm A)	prdncovypu(csjgaprnga) = was improved or maintained (change from baseline≤0) for most patients (81.5% [97/119]) at Week 52 ombtdudrnm (veoieztrry )	Positive	15 Nov 2022
NCT04161495 (XTEND-1, ASH 12022 \| ASH 22022) Manual	Phase 3	Pain \| Hemophilia A	159	Efanesoctocog alfa (Arm B)		Positive	15 Nov 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis